Lucinde R
Abdi A
Orindi B
Mwakio S
Gathuri H
Onyango E
Chira S
Ogero M
Isaaka L
Shangala J
Oginga IN
Wachira A
Manuthu E
Kariuki H
Nyikuli J
Wekesa C
Otedo A
Bosire H
Okoth SB
Ongalo W
Mukabi D
Lusamba W
Muthui B
Kirui N
Adembesa I
Mithi C
Sood M
Ahmed N
Gituma B
Ongaki VB
Giabe M
Omondi C
Ombajo LA
Kagucia W
English M
Hamaluba M
Ochola-Oyier LI
Kamuya D
Bejon P
Agweyu A
Akech S
Etyang AO
Wellcome Open Res. 2025;7269
BACKGROUND: Mortality among adults admitted to hospital with community acquired pneumonia in resource-limited settings is high. Recent studies conducted in high-income settings have demonstrated beneficial effects of low-dose corticosteroids in reducing mortality in patients with severe community acquired pneumonia. It is unknown whether these findings apply to low-income settings such as sub-Saharan Africa.This pragmatic randomized-controlled open-label trial will determine the effect of adjunctive low-dose corticosteroids in the management of adults admitted to hospital with community acquired pneumonia on mortality 30-days post-randomization. METHODS: We will enroll and randomize 2180 patients admitted with a diagnosis of community acquired pneumonia into two arms: the control and intervention arm. Those in the control arm will receive standard care for the treatment of community acquired pneumonia i.e., combination therapy with a beta-lactam and macrolide antibiotic. Those in the intervention arm will receive up to 10-days treatment with low-dose oral corticosteroids in addition to standard care. All participants will be followed up to 30- days post randomization and their final status recorded (alive or dead). DISCUSSION: If adjunctive low-dose oral corticosteroids are found to be beneficial, this easily scalable intervention would significantly reduce the currently high mortality associated with community acquired pneumonia.Pan-African Clinical Trials Registry: PACTR202111481740832; ISRCTRN registry: ISRCTN36138594.
